Deep Dives
Deep Dives
Stop FollowingDeep Dives
View as an RSS Feed
- Pssstt! Pfizer Is Not Executing And Is Overvalued
- No Major Concerns With HCA's Preliminary Numbers
- Rite Aid Reports Earnings Surprise As Revenues Continue To Slide
- FDA Designation May Accelerate Palbociclib Timeline But Not Increase Approval Probability
- Rite Aid Sales Continue To Erode
-
A Critical Analysis Of Pfizer's Pipeline, Earnings And Valuation
- Walgreen's Strong March Is Business As Usual
- What's Next For Cardinal Health?
- Walgreen Offers Surprises On 2 Fronts
- We Hate To Ring The Bell But These Pharmacy Stocks Appear Overvalued
- Pfizer Gains Notable Win And A Loss In Recent Pipeline Updates
- Rite Aid Increasingly Inconsequential With February Sales Figures
- Celebrex Ruling Is A Windfall For Pfizer
- Pfizer's Stake In HIV Breakthrough
- Walgreen Maintains Momentum With February Sales
- Pfizer's Cash Position Is Signaling Activity
- Walgreen Catalysts Missed By Wall Street
- HCA Secondary Offering Is Largely A Non-Event
- Pfizer's Increasing Cash May Signify More Repurchases Or A One-Time Dividend
- HCA's Exceptional Q4 Execution
- Walgreen's January Sales Explode But Rite Aid Flat
- HCA Holdings Perfect Confluence For Fiscal 4Q12
- Pfizer Surprises But Outlook Remains Uninspiring
- Pfizer's Post-2012 View Remains Void Of Necessary Catalysts
